blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3565558

EP3565558 - COMBINATION THERAPY WITH A SERD COMPOUND AND A CDK4/6 INHIBITOR FOR THE TREATMENT OF CANCER [Right-click to bookmark this link]
Former [2019/46]COMBINATION THERAPY FOR THE TREATMENT OF CANCER
[2023/13]
StatusThe patent has been granted
Status updated on  03.11.2023
Database last updated on 26.07.2024
FormerGrant of patent is intended
Status updated on  06.08.2023
FormerExamination is in progress
Status updated on  17.07.2023
FormerGrant of patent is intended
Status updated on  14.03.2023
FormerExamination is in progress
Status updated on  11.06.2021
FormerRequest for examination was made
Status updated on  11.10.2019
FormerThe international publication has been made
Status updated on  13.07.2018
Most recent event   Tooltip26.07.2024Lapse of the patent in a contracting state
New state(s): AT, CZ, RO		published on 28.08.2024 [2024/35]
Applicant(s)For all designated states
G1 Therapeutics, Inc.
79 TW Alexander Drive 4501
Research Commons
Suite 100
Research Triangle Park
NC 27709 / US
For all designated states
The Board of Trustees of the University of Illinois
352 Henry Administration Building
506 South Wright Street
Urbana, IL 61801 / US
[2019/46]
Inventor(s)01 / STRUM, Jay, C.
c/o G1 Therapeutics, Inc.
79 TW Alexander Drive
4501 Triangle Park, Suite 100
Research Triangle Park NC 27709 / US
02 / THATCHER, Gregory, R.
c/o The Board of Trustees of the
University of Illinois
352 Henry Administration Building
506 Wright Street
Urbana IL 61801 / US
03 / XIONG, Rui
c/o The Board of Trustees of the
University of Illinois
352 Henry Administration Building
506 Wright Street
Urbana IL 61801 / US
04 / ZHAO, Jiong
c/o The Board of Trustees of the
University of Illinois
352 Henry Administration Building
506 Wright Street
Urbana IL 61801 / US
05 / TONETTI, Debra, A.
c/o The Board of Trustees of the
University of Illinois
352 Henry Administration Building
506 Wright Street
Urbana IL 61801 / US
 [2023/49]
Former [2019/46]01 / STRUM, Jay, C.
c/o G1 Therapeutics Inc.
79 TW Alexander Drive
4501 Triangle Park Suite 100
Research Triangle Park NC 27709 / US
02 / THATCHER, Gregory, R.
c/o The Board of Trustees of the
University of Illinois
352 Henry Administration Building
506 Wright Street
Urbana IL 61801 / US
03 / XIONG, Rui
c/o The Board of Trustees of the
University of Illinois
352 Henry Administration Building
506 Wright Street
Urbana IL 61801 / US
04 / ZHAO, Jiong
c/o The Board of Trustees of the
University of Illinois
352 Henry Administration Building
506 Wright Street
Urbana IL 61801 / US
05 / TONETTI, Debra, A.
c/o The Board of Trustees of the
University of Illinois
352 Henry Administration Building
506 Wright Street
Urbana IL 61801 / US
Representative(s)Bassil, Nicholas Charles, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[2019/46]
Application number, filing date18736115.905.01.2018
[2019/46]
WO2018US12675
Priority number, dateUS201762443588P06.01.2017         Original published format: US 201762443588 P
[2019/46]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018129387
Date:12.07.2018
Language:EN
[2018/28]
Type: A1 Application with search report 
No.:EP3565558
Date:13.11.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 12.07.2018 takes the place of the publication of the European patent application.
[2019/46]
Type: B1 Patent specification 
No.:EP3565558
Date:06.12.2023
Language:EN
[2023/49]
Search report(s)International search report - published on:US12.07.2018
(Supplementary) European search report - dispatched on:EP24.07.2020
ClassificationIPC:A61K31/381, A61K31/519, C07D487/14, A61P35/00
[2020/35]
CPC:
A61P35/00 (EP,EA,IL,KR,US); A61K31/381 (EP,EA,IL,KR,US); A61K31/519 (EP,EA,IL,KR,US);
A61K31/5377 (EA,IL,KR,US); A61K45/06 (IL,KR); A61K2300/00 (IL,KR)
C-Set:
A61K31/381, A61K2300/00 (EP);
A61K31/519, A61K2300/00 (EP)
Former IPC [2019/46]A61K31/519, C07D487/14
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/46]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:KOMBINATIONSTHERAPIE MIT EINER SERD-VERBINDUNG UND EINEM CDK4/6-HEMMER ZUR BEHANDLUNG VON KREBS[2023/13]
English:COMBINATION THERAPY WITH A SERD COMPOUND AND A CDK4/6 INHIBITOR FOR THE TREATMENT OF CANCER[2023/13]
French:POLYTHÉRAPIE AVEC UN COMPOSÉ SERD ET UN INHIBITEUR CDK4/6 POUR LE TRAITEMENT DU CANCER[2023/13]
Former [2019/46]KOMBINATIONSTHERAPIE ZUR BEHANDLUNG VON KREBS
Former [2019/46]COMBINATION THERAPY FOR THE TREATMENT OF CANCER
Former [2019/46]POLYTHÉRAPIE POUR LE TRAITEMENT DU CANCER
Entry into regional phase31.07.2019National basic fee paid 
31.07.2019Search fee paid 
31.07.2019Designation fee(s) paid 
31.07.2019Examination fee paid 
Examination procedure31.07.2019Examination requested  [2019/46]
19.02.2021Amendment by applicant (claims and/or description)
15.06.2021Despatch of a communication from the examining division (Time limit: M06)
17.12.2021Reply to a communication from the examining division
29.03.2022Despatch of a communication from the examining division (Time limit: M04)
05.08.2022Reply to a communication from the examining division
15.03.2023Communication of intention to grant the patent
14.07.2023Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
07.08.2023Communication of intention to grant the patent
26.10.2023Fee for grant paid
26.10.2023Fee for publishing/printing paid
26.10.2023Receipt of the translation of the claim(s)
Fees paidRenewal fee
14.01.2020Renewal fee patent year 03
13.01.2021Renewal fee patent year 04
17.12.2021Renewal fee patent year 05
27.01.2023Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT06.12.2023
CZ06.12.2023
EE06.12.2023
ES06.12.2023
HR06.12.2023
LT06.12.2023
LV06.12.2023
NL06.12.2023
RO06.12.2023
RS06.12.2023
SE06.12.2023
SM06.12.2023
BG06.03.2024
NO06.03.2024
GR07.03.2024
IS06.04.2024
[2024/35]
Former [2024/34]EE06.12.2023
ES06.12.2023
HR06.12.2023
LT06.12.2023
LV06.12.2023
NL06.12.2023
RS06.12.2023
SE06.12.2023
SM06.12.2023
BG06.03.2024
NO06.03.2024
GR07.03.2024
IS06.04.2024
Former [2024/33]ES06.12.2023
HR06.12.2023
LT06.12.2023
LV06.12.2023
NL06.12.2023
RS06.12.2023
SE06.12.2023
SM06.12.2023
BG06.03.2024
NO06.03.2024
GR07.03.2024
IS06.04.2024
Former [2024/32]ES06.12.2023
HR06.12.2023
LT06.12.2023
LV06.12.2023
NL06.12.2023
RS06.12.2023
SE06.12.2023
BG06.03.2024
NO06.03.2024
GR07.03.2024
IS06.04.2024
Former [2024/26]ES06.12.2023
HR06.12.2023
LT06.12.2023
LV06.12.2023
NL06.12.2023
RS06.12.2023
SE06.12.2023
BG06.03.2024
NO06.03.2024
GR07.03.2024
Former [2024/24]ES06.12.2023
HR06.12.2023
LT06.12.2023
RS06.12.2023
SE06.12.2023
BG06.03.2024
NO06.03.2024
GR07.03.2024
Former [2024/21]LT06.12.2023
BG06.03.2024
GR07.03.2024
Former [2024/20]GR07.03.2024
Documents cited:Search[Y]WO2016010848  (QUALCOMM INC [US]) [Y] 1-28 * claims 1-6, 13, 21, 22, 30, 34 *;
 [YP]WO2017100712  (UNIV ILLINOIS [US]) [YP] 1-28 * claims 1, 22, 24-26, 31-38, 40 *;
 [Y]  - S. E. WARDELL ET AL, "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer", CLINICAL CANCER RESEARCH, US, (20150519), vol. 21, no. 22, doi:10.1158/1078-0432.CCR-15-0360, ISSN 1078-0432, pages 5121 - 5130, XP055555127 [Y] 1-28 * abstract * * Translational relevance; page 5122 * * figure 4 * * page 5127, column 2, paragraph 2 * * page 5128, column 1, paragraph 2 - column 2, paragraph 1 *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-15-0360
 [Y]  - Anonymous, "History of Changes for Study: NCT02983071 - G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer", Clinical Trials.gov archive, (20161207), pages 1 - 5, URL: https://www.clinicaltrials.gov/ct2/history/NCT02983071?V_2=View#StudyPageTop, (20200714), XP055714462 [Y] 1-28 * Study description; page 2 * * Arms and interventions; pages 2-3 *
 [XPY]  - S. Wardell ET AL, "Abstract 5641: Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in animal models of endocrine resistant breast cancer", Cancer Research, (20170401), pages 1 - 4, URL: https://cancerres.aacrjournals.org/content/77/13_Supplement/5641, (20200714), XP055714473 [XP] 1-4,9,10,14,17,20,21,26 * the whole document * [Y] 1-28

DOI:   http://dx.doi.org/10.1158/1538-7445.AM2017-5641
 [XPY]  - RUI XIONG ET AL, "Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer", JOURNAL OF MEDICINAL CHEMISTRY, US, (20170124), vol. 60, no. 4, doi:10.1021/acs.jmedchem.6b01355, ISSN 0022-2623, pages 1325 - 1342, XP055534037 [XP] 1-4,10,12,19,20,22,28 * abstract * * tables 2, 3; compounds 28a, 24c, 28c * * figure 7 * * page 1334, column 2, paragraph 2 * * page 1335, column 2, paragraph 1 * * page 1336, column 1, paragraph 2 * * page 1336, column 2, paragraph 2 * [Y] 1-28

DOI:   http://dx.doi.org/10.1021/acs.jmedchem.6b01355
 [T]  - ANDREANO KAITLYN J ET AL, "G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer", BREAST CANCER RESEARCH AND TREATMENT, SPRINGER , NY, US, vol. 180, no. 3, doi:10.1007/S10549-020-05575-9, ISSN 0167-6806, (20200304), pages 635 - 646, (20200304), XP037077693 [T] * abstract * * page 636, column 1, paragraph l * * page 641, column 2, paragraph 1 * * figure 5 * * page 644, column 2, paragraph 2 *

DOI:   http://dx.doi.org/10.1007/s10549-020-05575-9
International search[Y]US2014235660  (BURKS HEATHER ELIZABETH [US], et al) [Y] 1-18, 19/1-18, 28, 30, 32/28, 32/30, 37, 39, 41/37, 41/39, 46-48, 49/47-48, 50/47-48, 51/47-48, 52/47-48 * ; paragraphs [0007]-[0015], [0019], [0021], [0025]-[0026], [0030], [0056]-[0059], [0061]-[0066], [0076], [0083]-[0085], [0087]-[0088], [0094], [0100], [0212], [0215] *;
 [Y]US2014271460  (SHARPLESS NORMAN E [US], et al) [Y] 1-18, 19/1-18, 28, 30, 32/28, 32/30, 37, 39, 41/37, 41/39, 46-48, 49/47-48, 50/47-48, 51/47-48, 52/47-48* ; paragraphs [0095], [0125], [0168] *;
 [Y]US2015291552  (THATCHER GREGORY R [US], et al) [Y] 1-18, 19/1-18, 28, 30, 32/28, 32/30, 37, 39, 41/37, 41/39, 46-48, 49/47-48, 50/47-48, 51/47-48, 52/47-48 * ; paragraphs [0005]-[0012], [0036] *
by applicantEP0545478
 EP0551849
 EP0622673
 US5491123
 EP0752421
 EP0802184
 US5780497
 US5880137
 WO9924027
 US5998402
 US6005102
 US6326392
 US2001056099
 WO0204418
 WO0203992
 WO0203991
 WO0203990
 WO0203989
 WO0203988
 WO0203986
 WO0203977
 WO0203976
 WO0203975
 US2002013327
 US2002016340
 WO0213802
 US2002128276
 US6479535
 US6512002
 US6583170
 US6632834
 US6756401
 US6777424
 US6821989
 WO2005016929
 JP2005129430
 WO2006078834
 WO2006084338
 US2007112009
 WO2007087684
 EP1947085
 WO2009013195
 WO2010075542
 WO2010093578
 WO2010127452
 WO2012048058
 WO2012084711
 US8598186
 US8598197
 WO2014191726
 US2015258080
 US2016175289
 US9481691
 US2017166550
 US2017166551
 WO2017100712
 WO2017100715
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.